Cardiovascular and renal effects of acute administration of a new hypotensive compound, guancydine.
D000284:Administration, Oral; D000618:Aminohippuric Acids / Q000097:blood / Q000652:urine; D000804:Angiotensin II / Q000037:antagonists & inhibitors; D001794:Blood Pressure / Q000187:drug effects; D005919:Glomerular Filtration Rate; D006146:Guanidines / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007668:Kidney / Q000187:drug effects*; D007677:Kidney Function Tests; D009570:Nitriles / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D011187:Posture; D011188:Potassium / Q000097:blood / Q000652:urine; D012964:Sodium / Q000097:blood / Q000652:urine; D014882:Water-Electrolyte Balance / Q000187:drug effects
D000618:Aminohippuric Acids; D006146:Guanidines; D009570:Nitriles; D000804:Angiotensin II; D012964:Sodium; D011188:Potassium; D009638:Norepinephrine